Yes, when given under medical supervision with proper screening
[1] Relative Contraindications Requiring In-Person Specialist Input Women with active gallbladder disease, a history of pancreatitis, or severe gastroparesis should discuss those conditions with a gastroenterologist before starting a GLP-1 agent through any platform, telehealth or brick-and-mortar
Instead of a one-size-fits-all protocol, it lets you build your own plan: first choosing the med type, then the active compound, followed by optional longevity-focused additives
Metabolic Flexibility Research: Examination of cellular adaptation to varying energy substrates, fasting-to-fed transitions, and exercise-induced metabolic shifts
GLP-1s account for 23% of first line diabetes therapy in 2025 up from 3% in 2021 Since 2019, the American Diabetes Association (ADA) has revised its Standards of Care each year to expand the role of GLP-1 receptor agonists and SGLT2 inhibitors as first-line treatments for T2D 2
